sulfathiourea: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
sulfathiourea : A substituted aniline that is thiourea in which one of the hydrogens has been replaced by a (p-aminophenyl)sulfonyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 3000579 |
| CHEMBL ID | 2107489 |
| CHEBI ID | 131723 |
| SCHEMBL ID | 149742 |
| MeSH ID | M0084432 |
| Synonym |
|---|
| NCGC00181137-01 |
| sulfathiourea (inn) |
| D07239 |
| 4-amino-n-(aminothioxomethyl)-benzenesulfonamide |
| (4-aminophenyl)sulfonylthiourea |
| baldinol |
| sulfanilthiourea |
| sulfanilamide, n(sup1)-(thiocarbamoyl)- |
| solufontamide |
| sulfathiourea |
| benzenesulfonamide, 4-amino-n-(aminothioxomethyl)- |
| sulfanilthiocarbamide |
| p-aminobenzenesulfonylthiourea |
| r.p. 2255 |
| sulfathiocarbamid |
| sulphathiourea |
| badional |
| urea, 1-sulfanilyl-2-thio- |
| 515-49-1 |
| nsc-108228 |
| salvoseptyl |
| p-aminophenylsulfonylthiourea |
| sulfathiocarbamide |
| nsc108228 |
| fontamide |
| 1-sulfanilyl-2-thiourea |
| sulfathiourea [inn-latin] |
| sulfatiourea [inn-spanish] |
| brn 2696478 |
| einecs 208-201-7 |
| solfatiourea [dcit] |
| 2-sulfanilamidothiokarbamid [german] |
| 4-amino-n-(aminothioxomethyl)benzenesulfonamide |
| nsc 108228 |
| sulfathiouree [inn-french] |
| sulfathiocarbamidum |
| rp 2255 |
| rp-2255 |
| sulfatiourea |
| 4-amino-n-carbamothioylbenzenesulfonamide |
| sulfathiouree |
| 2-sulfanilamidothiokarbamid |
| CHEBI:131723 |
| unii-mxf9g4i1v5 |
| solfatiourea |
| mxf9g4i1v5 , |
| sulfathiourea [inn:ban:dcf] |
| 4-14-00-02671 (beilstein handbook reference) |
| dtxcid2026868 |
| cas-515-49-1 |
| dtxsid4046868 , |
| tox21_112744 |
| CHEMBL2107489 |
| sulfathiourea [who-dd] |
| sulfathiourea [inn] |
| sulfathiourea [mi] |
| SCHEMBL149742 |
| W-105880 |
| gtpl12745 |
| DB13699 |
| Q6577324 |
| STARBLD0005628 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Role | Description |
|---|---|
| antibacterial drug | A drug used to treat or prevent bacterial infections. |
| EC 2.5.1.15 (dihydropteroate synthase) inhibitor | An EC 2.5.1.* (non-methyl-alkyl or aryl transferase) inhibitor that interferes with the action of dihydropteroate synthase (EC 2.5.1.15), an enzyme that catalyzes the formation of dihydropteroate from p-aminobenzoic acid and dihydropteridine-hydroxymethyl-pyrophosphate. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| sulfonamide antibiotic | A class of sulfonamides whose members generally have bacteriostatic antibiotic properties. |
| thioureas | Compounds of general formula RR'NC(=S)NR''R'''. |
| substituted aniline | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 50.1187 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 3.1623 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 9 (69.23) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (16.47) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 16 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||